Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
Chloe Orkin, Jean Michel Molina, Pedro Cahn, DRIVE-FORWARD and DRIVE-AHEAD collaborators, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar, Havilland Campbell, Hong Wan, Valerie Teal, Zhi Jin Xu, Ernest Asante-Appiah, Peter Sklar, Hedy Teppler, Rima Lahoulou*, Marcelo D. Martins, Pedro E. Cahn, Gustavo D. Lopardo, Norma Porteiro, Mark Theo BlochDavid Alfred Baker, Norman Roth, Richard J. Moore, Robert James Finlayson, James McMahon, Armin Rieger, Alexander Zoufaly, Brigitte Schmied, Sylvia Hartl, Robert Zangerle, Fiona Smaill, Sharon L. Walmsley, Brian Conway, Anita Rachlis, Graham H.R. Smith, Carlos Perez Cortes, Alejandro Afani, Maria Isabel E. Campos Barker, Carolina Eugenia Chahin Anania, Marcelo J.Wolff Reyes, Jan Gerstoft, Nina Weis, Alex Lund Laursen, Yazdan Yazdanpanah, Laurent Cotte, Francois Raffi, Laurence Slama, Philippe Morlat, Pierre Marie Girard, Bart Rijnders, Jan G. den Hollander
Research output: Contribution to journal › Article › Academic › peer-review
7Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials'. Together they form a unique fingerprint.